Supplements and Featured Publications
Newsletter - Inflammation, Metabolic Syndrome, and CV Risk Reduction
Volume 10
Issue 2 Metab

Faculty Disclosure Statement

Dr Dunbar: Speakers' bureau: Kos, Pfizer; Dr Szapary: Grants/research support: Takeda; Speakers' bureau: Takeda, Pfizer; Dr Haffner: Reported no financial support; Dr Rader: Consultant/grants/research support: Abbott, AstraZeneca, Bristol-Myers Squibb, Fournier, Kos, Merck, Pfizer, Schering-Plough; Speakers' bureau: Abbott, AstraZeneca, Bristol-Myers Squibb, Kos, Merck, Pfizer, Schering-Plough.

This report includes discussion of insulin sensitizers, including metformin and the thiazolidinediones, for preventing type 2 0diabetes, an indication not currently approved by the FDA.

CH LogoCenter for Biosimilars Logo